Lupin achieves top ESG score, setting new global standard in pharma

Lupin Limited announced on November 13, 2025, that it has attained an S&P Global ESG Score of 91, far surpassing the pharmaceutical industry average of 28. This achievement places Lupin in an exclusive group of companies worldwide with scores above the 90-point mark. The company's score reflects a remarkable increase from 17 in 2021, demonstrating one of the fastest rates of improvement among pharmaceutical companies.

The company's executive director, global cfo, and head of IT and API Plus SBU, Ramesh Swaminathan, highlighted that this 15-point increase from the previous year positions Lupin as a leader in sustainable growth and redefines standards for responsible growth in the pharmaceutical industry. Lupin attributes its progress to significant efforts across environmental, social, and governance pillars, including increased renewable energy use, reduced carbon emissions, water-positive operations, and enhanced corporate transparency.

Lupin, headquartered in Mumbai, India, distributes products in over 100 markets, specializing in various pharmaceutical products and employing over 24,000 professionals globally. The company's commitment to improving patient health outcomes is delivered through its subsidiaries: Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.